{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:45:18Z","timestamp":1785548718674,"version":"3.56.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CI 2005-0308007"],"award-info":[{"award-number":["CI 2005-0308007"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI020499"],"award-info":[{"award-number":["PI020499"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI050427"],"award-info":[{"award-number":["PI050427"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI060507"],"award-info":[{"award-number":["PI060507"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019270","name":"Fundaci\u00f3n Marqu\u00e9s de Valdecilla","doi-asserted-by":"publisher","award":["API07\/011"],"award-info":[{"award-number":["API07\/011"]}],"id":[{"id":"10.13039\/501100019270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.schres.2017.01.046","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T12:45:36Z","timestamp":1487681136000},"page":"134-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1 year study"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9207-4776","authenticated-orcid":false,"given":"Benedicto","family":"Crespo-Facorro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Ortiz-Garcia de la Foz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Suarez-Pinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa M.","family":"Valdizan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"P\u00e9rez-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Amado-Se\u00f1aris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Teresa Garcia-Unzueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Labad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Ayesa-Arriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2017.01.046_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary Depression Scale","volume":"22","author":"Addington","year":"1993","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.schres.2017.01.046_bb0010","series-title":"Scale for the Assessment of Negative Symptoms (Sans)","author":"Andreasen","year":"1983"},{"key":"10.1016\/j.schres.2017.01.046_bb0015","series-title":"Scale for the Assessment of Positive Symptoms (Saps)","author":"Andreasen","year":"1984"},{"issue":"7","key":"10.1016\/j.schres.2017.01.046_bb0020","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.pnpbp.2010.02.019","article-title":"Hyperprolactinaemia in early psychosis-not only due to antipsychotics","volume":"34","author":"Aston","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.01.046_bb0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0165-3806(84)90039-7","article-title":"A developmental study of adenohypophyseal dopaminergic receptors and of haloperidol-induced prolactin release in rats","volume":"314","author":"Becu de Villalobos","year":"1984","journal-title":"Brain Res."},{"issue":"6","key":"10.1016\/j.schres.2017.01.046_bb0030","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr. Rev."},{"issue":"2","key":"10.1016\/j.schres.2017.01.046_bb0035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1095\/biolreprod15.2.168","article-title":"Age and sex differences in prolactin response to phenothiazines in rats","volume":"15","author":"Bohnet","year":"1976","journal-title":"Biol. Reprod."},{"issue":"1","key":"10.1016\/j.schres.2017.01.046_bb0040","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.01.046_bb0045","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","article-title":"Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study","volume":"107","author":"Byerly","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2017.01.046_bb0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"58","author":"Chen","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.schres.2017.01.046_bb0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00213-011-2392-3","article-title":"Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis","volume":"219","author":"Crespo-Facorro","year":"2012","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.schres.2017.01.046_bb0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40120-016-0050-8","article-title":"Current data on and clinical insights into the treatment of first episode nonaffective psychosis: a comprehensive review","volume":"5","author":"Crespo-Facorro","year":"2016","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.schres.2017.01.046_bb8875","series-title":"Structured Clinical Interview for Dsm-Iv-Tr Axis I Disorders-Non-Patient Edition","author":"First","year":"2001"},{"issue":"4","key":"10.1016\/j.schres.2017.01.046_bb0065","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/mp.2010.37","article-title":"Exploring functional polymorphisms in the dopamine receptor D2 gene using prolactin concentration in healthy subjects","volume":"16","author":"Fukui","year":"2011","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.01.046_bb0070","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/0269881110372817","article-title":"A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia","volume":"25","author":"Gopal","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2017.01.046_bb0075","doi-asserted-by":"crossref","first-page":"T101","DOI":"10.1530\/JOE-15-0213","article-title":"60 YEARS OF NEUROENDOCRINOLOGY: the hypothalamo-prolactin axis","volume":"226","author":"Grattan","year":"2015","journal-title":"J. Endocrinol."},{"issue":"1\u20133","key":"10.1016\/j.schres.2017.01.046_bb0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2006.06.021","article-title":"Olanzapine and haloperidol in first episode psychosis: two-year data","volume":"86","author":"Green","year":"2006","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2017.01.046_bb0085","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/schbul\/sbp037","article-title":"Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial","volume":"37","author":"Grootens","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2017.01.046_bb0090","first-page":"s120","article-title":"International clinical practice guidelines for early psychosis","volume":"48","author":"Group., I.E.P.A.W","year":"2005","journal-title":"Br. J. Psychiatry Suppl."},{"issue":"1","key":"10.1016\/j.schres.2017.01.046_bb0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0006-3223(98)00125-5","article-title":"Neuroendocrine response to antipsychotics: effects of drug type and gender","volume":"45","author":"Grunder","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2017.01.046_bb0100","series-title":"Ecdeu Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"9618","key":"10.1016\/j.schres.2017.01.046_bb0105","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.schres.2017.01.046_bb0110","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/eoid.12.4.655.23750","article-title":"Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic","volume":"12","author":"Keck","year":"2003","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.schres.2017.01.046_bb0115","doi-asserted-by":"crossref","first-page":"8902","DOI":"10.1038\/srep08902","article-title":"Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs","volume":"5","author":"Kucka","year":"2015","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.schres.2017.01.046_bb0120","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1681.1992.tb00511.x","article-title":"A study of serum prolactin levels in schizophrenia: comparison of males and females","volume":"19","author":"Kuruvilla","year":"1992","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"1","key":"10.1016\/j.schres.2017.01.046_bb0125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1440-1819.2008.01907.x","article-title":"Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study","volume":"63","author":"Kwon","year":"2009","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2017.01.046_bb0130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jpsychires.2014.10.011","article-title":"Stress biomarkers as predictors of transition to psychosis in at-risk mental states: roles for cortisol, prolactin and albumin","volume":"60","author":"Labad","year":"2015","journal-title":"J. Psychiatr. Res."},{"issue":"9896","key":"10.1016\/j.schres.2017.01.046_bb0135","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2017.01.046_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"2","key":"10.1016\/j.schres.2017.01.046_bb0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/YIC.0000000000000063","article-title":"Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents","volume":"30","author":"Margari","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2017.01.046_bb0150","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4088\/JCP.v69n0515","article-title":"Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies","volume":"69","author":"Meltzer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2017.01.046_bb0155","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4088\/JCP.v68n1115","article-title":"The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update","volume":"68","author":"Moore","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.01.046_bb0160","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1210\/endo-100-2-427","article-title":"Prolactin release in response to blockade of dopaminergic receptors and to TRH injection in developing and adult rats: role of estrogen in determining sex differences","volume":"100","author":"Ojeda","year":"1977","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.schres.2017.01.046_bb0165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S1461145704004262","article-title":"A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis","volume":"7","author":"Oosthuizen","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2017.01.046_bb0170","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"issue":"3","key":"10.1016\/j.schres.2017.01.046_bb0175","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1751-7893.2008.00074.x","article-title":"Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis","volume":"2","author":"Pelayo-Teran","year":"2008","journal-title":"Early Interv. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2017.01.046_bb0180","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/JCP.0b013e318272688b","article-title":"Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis","volume":"32","author":"Perez-Iglesias","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2017.01.046_bb0185","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2014.07.045","article-title":"Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12weeks of treatment in first treated episode of psychosis","volume":"159","author":"Perez-Iglesias","year":"2014","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.schres.2017.01.046_bb0190","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"issue":"12","key":"10.1016\/j.schres.2017.01.046_bb0195","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1017\/S0033291713000226","article-title":"Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis","volume":"43","author":"Riecher-Rossler","year":"2013","journal-title":"Psychol. Med."},{"issue":"3","key":"10.1016\/j.schres.2017.01.046_bb0200","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/schbul\/sbi032","article-title":"Pharmacological treatments for first-episode schizophrenia","volume":"31","author":"Robinson","year":"2005","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.schres.2017.01.046_bb0205","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/schbul\/sbv125","article-title":"A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes","volume":"41","author":"Robinson","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2017.01.046_bb0210","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","article-title":"Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial","volume":"162","author":"Schooler","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2017.01.046_bb0215","first-page":"575","article-title":"Diagnosis and management of hyperprolactinemia","volume":"169","author":"Serri","year":"2003","journal-title":"CMAJ"},{"issue":"5","key":"10.1016\/j.schres.2017.01.046_bb0220","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1095\/biolreprod54.5.987","article-title":"Sexual differences in the diurnal changes of tuberoinfundibular dopaminergic neuron activity in the rat: role of cholinergic control","volume":"54","author":"Shieh","year":"1996","journal-title":"Biol. Reprod."},{"issue":"9","key":"10.1016\/j.schres.2017.01.046_bb0225","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2017.01.046_bb0230","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.pnpbp.2010.07.003","article-title":"Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients","volume":"34","author":"Suzuki","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2017.01.046_bb0235","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S0033291709990407","article-title":"Weight gain in antipsychotic-naive patients: a review and meta-analysis","volume":"40","author":"Tarricone","year":"2010","journal-title":"Psychol. Med."},{"issue":"11","key":"10.1016\/j.schres.2017.01.046_bb0240","doi-asserted-by":"crossref","first-page":"992","DOI":"10.4088\/JCP.v63n1106","article-title":"Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade","volume":"63","author":"Tauscher-Wisniewski","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2017.01.046_bb0245","first-page":"929","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"Torre","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"issue":"2","key":"10.1016\/j.schres.2017.01.046_bb0250","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/JCP.0b013e31820e4832","article-title":"Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion","volume":"31","author":"Veselinovic","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2017.01.046_bb0255","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2017.01.046_bb0260","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-0447.1995.tb09758.x","article-title":"Galactorrhea: subjective response by schizophrenic patients","volume":"91","author":"Wesselmann","year":"1995","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2017.01.046_bb0265","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2017.01.046_bb0270","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/YIC.0b013e3283528d22","article-title":"Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial","volume":"27","author":"Zhao","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.schres.2017.01.046_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139717","article-title":"Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week randomized, open-label, comparative clinical trial","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS One"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417300592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417300592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T08:03:46Z","timestamp":1656835426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417300592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":56,"alternative-id":["S0920996417300592"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.01.046","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.01.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}